NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING
Phase 1 clinical study data on NRL-1049 shows dose-proportional increase in exposure and favorable safety profile San Diego, CA – November 6, 2025 – Neurelis, Inc., today announced it will present at the Alliance to Cure Cavernous Malformation (CCM) 21st International CCM Scientific & Clinical Meeting to be held November 6-7, 2025, in Atlanta, Georgia. […]